Department of Oncology, Qingdao Cancer Institute, The Affiliated Hospital of Qingdao University, Qingdao, China.
Hum Vaccin Immunother. 2023 Aug 1;19(2):2246498. doi: 10.1080/21645515.2023.2246498.
Immunotherapy has revolutionized cancer treatment. B7-H3 is a promising target for cancer immunotherapy (CI). The present study aimed to utilize bibliometric methods to assess the current research status and explore future trends in the use of B7-H3 for CI. We collected publications related to B7-H3/CI from the Clarivate Web of Science Core Collection database. VOSviewer, Microsoft Excel, the bibliometrix R package, and an online platform were used to conduct qualitative and visualized analyses of the literature. A total of 555 papers were analyzed, revealing a significant increase in annual publications since 2018. The most productive countries were China and the USA, and the leading institutions were Soochow University and Sichuan University. Zang and Ferrone were the most popular authors. Among the journals, had the highest number of papers, whereas was the most influential. Historical citation analysis reveals the development of B7-H3/CI. Top-cited papers and keyword analyses were performed to highlight current hotspots in the domain. Using cluster analysis, we classified all keywords into four clusters: "immunotherapy," "co-stimulatory molecule," "B7 family," and "PD-L1." Finally, Trends analysis suggested that future research might focus on "chimeric antigen receptor," "pathways," and "targeting B7-H3." This is the first bibliometric crosstalk analysis between B7-H3 and CI. Our study illustrates that the topic of B7-H3/CI is very popular and has great clinical implications and that the number of correlative publications will continue to increase. B7-H3-based CI may lead to new research trends.
免疫疗法已经彻底改变了癌症治疗。B7-H3 是癌症免疫治疗 (CI) 的一个有前途的靶点。本研究旨在利用文献计量学方法评估 B7-H3 用于 CI 的当前研究现状并探索未来趋势。我们从科睿唯安 Web of Science 核心合集数据库中收集了与 B7-H3/CI 相关的出版物。使用 VOSviewer、Microsoft Excel、bibliometrix R 包和在线平台对文献进行定性和可视化分析。共分析了 555 篇论文,显示自 2018 年以来年度出版物数量显著增加。最具生产力的国家是中国和美国,领先的机构是苏州大学和四川大学。Zang 和 Ferrone 是最受欢迎的作者。在期刊中, 发表的论文数量最多,而 是最有影响力的期刊。历史引文分析揭示了 B7-H3/CI 的发展。对高被引论文和关键词分析突出了该领域的当前热点。使用聚类分析,我们将所有关键词分为四个聚类:“免疫疗法”、“共刺激分子”、“B7 家族”和“PD-L1”。最后,趋势分析表明,未来的研究可能集中在“嵌合抗原受体”、“途径”和“靶向 B7-H3”上。这是 B7-H3 和 CI 之间的首次文献计量交叉分析。我们的研究表明,B7-H3/CI 主题非常热门,具有重要的临床意义,相关出版物的数量将继续增加。基于 B7-H3 的 CI 可能会带来新的研究趋势。
Hum Vaccin Immunother. 2023-8-1
Front Endocrinol (Lausanne). 2023
Front Biosci (Landmark Ed). 2022-8-31
Medicine (Baltimore). 2023-7-7
J Hematol Oncol. 2022-10-25
Int Immunopharmacol. 2021-12
Front Immunol. 2021
Cell Stem Cell. 2021-9-2